Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone

Schizophrenia Clinical Trial

Official title:

A Randomized, Double Blind, Multi-Center Study to Assess the Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol or Risperidone to Schizophrenic Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00361166
• Other study ID #: ACP-103-008
• Status: Completed
• Phase: Phase 2
• First received: August 3, 2006
• Last updated: March 20, 2007
• Start date: August 2005
• Est. completion date: March 2007

Study information

• Verified date: March 2007
• Source: ACADIA Pharmaceuticals Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationBrazil: Ministry of HealthBrazil: National Committee of Ethics in Research
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this study is to determine whether a combination of ACP-103 (the study medication) with either haloperidol or risperidone will show antipsychotic efficacy and that it is safe and well tolerated. Further purposes of this study are to determine whether ACP-103, in combination with either haloperidol or risperidone, will enhance their antipsychotic effectiveness, demonstrate effectiveness against the negative symptoms, improve motoric tolerability, and is safe and well tolerated.

This is a seven-week study (one week screening and six weeks of study medication) where a total of 400 patients who meet entrance criteria will randomly be assigned to receive one of five groups of study treatments of either low dose haloperidol plus ACP-103, low dose haloperidol plus placebo (a substance similar to a sugar pill), low dose risperidone plus ACP-103, low dose risperidone plus placebo, or high dose risperidone plus placebo. The study will begin with with a three to seven day drug-free period followed by six weeks of a stable daily dosage of study medication. Study subjects will be treated as hospital in-patients during screening and for the first 14 days of the study. Study subjects will be closely monitored throughout the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 400
• Est. completion date: March 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• male or female subjects ages 18-65 diagnosed with schizophrenia

• experiencing an acute exacerbation of psychosis

• has had prior response to antipsychotic therapy within the previous 3 years

• female subjects must be of non-childbearing potential or must comply with double-barrier protection methods against conception

• ability of subject or caregiver or legally authorized representative to provide informed consent

• subjects must be hospitalized at screening and must be willing to remain in the hospital at least 14 days after baseline and must comply with all study events through completion of the study

Exclusion Criteria:

• inability of the subject or caregiver or legally authorized representative to provide consent

• any female subject who is pregnant or breast feeding

• any subject with concurrent mental illness or disability

• any subject considered to be a danger to themselves or others

• recent use of certain antipsychotics or other medications that might interfere with this study's medication

• abnormal clinical laboratory values

• presence, or recent history, of serious medical conditions or drug abuse

• likely allergy or sensitivity to ACP-103, haloperidol, or risperidone, based on known allergies to drugs of the same class

• any subject who has participated in a prior clinical trial of ACP-103

• any subject judged by the Principal Investigator to be inappropriate for the study

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Drug:
• ACP-103

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
ACADIA Pharmaceuticals Inc.

Countries where clinical trial is conducted

United States,  Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total score on the Positive and Negative Symptom Scale (PANSS).
Secondary	Clinical Global Impression-Severity (CGI-S), Simpson Angus Scale (SAS), Barnes Akathisia Scale (BAS), Calgary Depression Scale for Schizophrenia (CDSS)